Journal of Hematology & Oncology (Dec 2010)

Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia

  • Berthou Christian,
  • Meyer Michèle,
  • Le Ster Karine,
  • Loisel Séverine,
  • Youinou Pierre,
  • Kolb Jean-Pierre,
  • Billard Christian

DOI
https://doi.org/10.1186/1756-8722-3-49
Journal volume & issue
Vol. 3, no. 1
p. 49

Abstract

Read online

Abstract Background We previously reported that allanxanthone C and macluraxanthone, two xanthones purified from Guttiferae trees, display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic lymphocytic leukemia (CLL) and leukemia B cell lines. Results Here, we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of human CLL, developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant prolongation of their survival as compared to control animals injected with the solvent alone (p = 0.0006 and p = 0.0141, respectively). The same treatment of mice which were not xenografted induced no mortality. Conclusion These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones, and confirm their potential interest for CLL therapy.